Cargando…
Rhinovirus Type in Severe Bronchiolitis and the Development of Asthma
BACKGROUND: Respiratory syncytial virus (RSV)- and rhinovirus (RV)-induced bronchiolitis are associated with an increased risk of asthma, but more detailed information is needed on virus types. OBJECTIVE: To study whether RSV or RV types are differentially associated with the future use of asthma co...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012669/ https://www.ncbi.nlm.nih.gov/pubmed/31520837 http://dx.doi.org/10.1016/j.jaip.2019.08.043 |
_version_ | 1783496266587570176 |
---|---|
author | Bergroth, Eija Aakula, Matilda Elenius, Varpu Remes, Sami Piippo-Savolainen, Eija Korppi, Matti Piedra, Pedro A. Bochkov, Yury A. Gern, James E. Camargo, Carlos A. Jartti, Tuomas |
author_facet | Bergroth, Eija Aakula, Matilda Elenius, Varpu Remes, Sami Piippo-Savolainen, Eija Korppi, Matti Piedra, Pedro A. Bochkov, Yury A. Gern, James E. Camargo, Carlos A. Jartti, Tuomas |
author_sort | Bergroth, Eija |
collection | PubMed |
description | BACKGROUND: Respiratory syncytial virus (RSV)- and rhinovirus (RV)-induced bronchiolitis are associated with an increased risk of asthma, but more detailed information is needed on virus types. OBJECTIVE: To study whether RSV or RV types are differentially associated with the future use of asthma control medication. METHODS: Over 2 consecutive winter seasons (2008-2010), we enrolled 408 children hospitalized for bronchiolitis at age less than 24 months into a prospective, 3-center, 4-year follow-up study in Finland. Virus detection was performed by real-time reverse transcription PCR from nasal wash samples. Four years later, we examined current use of asthma control medication. RESULTS: A total of 349 (86%) children completed the 4-year follow-up. At study entry, the median age was 7.5 months, and 42% had RSV, 29% RV, 2% both RSV and RV, and 27% non-RSV/-RV etiology. The children with RV-A (adjusted hazard ratio, 2.3; P = .01), RV-C (adjusted hazard ratio, 3.5; P < .001), and non-RSV/-RV (adjusted hazard ratio, 2.0; P = .004) bronchiolitis started the asthma control medication earlier than did children with RSV bronchiolitis. Four years later, 27% of patients used asthma control medication; both RV-A (adjusted odds ratio, 3.0; P = .03) and RV-C (adjusted odds ratio, 3.7; P < .001) etiology were associated with the current use of asthma medication. The highest risk was found among patients with RV-C, atopic dermatitis, and fever (adjusted odds ratio, 5.0; P = .03). CONCLUSIONS: Severe bronchiolitis caused by RV-A and RV-C was associated with earlier initiation and prolonged use of asthma control medication. The risk was especially high when bronchiolitis was associated with RV-C, atopic dermatitis, and fever. |
format | Online Article Text |
id | pubmed-7012669 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Academy of Allergy, Asthma & Immunology |
record_format | MEDLINE/PubMed |
spelling | pubmed-70126692020-03-31 Rhinovirus Type in Severe Bronchiolitis and the Development of Asthma Bergroth, Eija Aakula, Matilda Elenius, Varpu Remes, Sami Piippo-Savolainen, Eija Korppi, Matti Piedra, Pedro A. Bochkov, Yury A. Gern, James E. Camargo, Carlos A. Jartti, Tuomas J Allergy Clin Immunol Pract Article BACKGROUND: Respiratory syncytial virus (RSV)- and rhinovirus (RV)-induced bronchiolitis are associated with an increased risk of asthma, but more detailed information is needed on virus types. OBJECTIVE: To study whether RSV or RV types are differentially associated with the future use of asthma control medication. METHODS: Over 2 consecutive winter seasons (2008-2010), we enrolled 408 children hospitalized for bronchiolitis at age less than 24 months into a prospective, 3-center, 4-year follow-up study in Finland. Virus detection was performed by real-time reverse transcription PCR from nasal wash samples. Four years later, we examined current use of asthma control medication. RESULTS: A total of 349 (86%) children completed the 4-year follow-up. At study entry, the median age was 7.5 months, and 42% had RSV, 29% RV, 2% both RSV and RV, and 27% non-RSV/-RV etiology. The children with RV-A (adjusted hazard ratio, 2.3; P = .01), RV-C (adjusted hazard ratio, 3.5; P < .001), and non-RSV/-RV (adjusted hazard ratio, 2.0; P = .004) bronchiolitis started the asthma control medication earlier than did children with RSV bronchiolitis. Four years later, 27% of patients used asthma control medication; both RV-A (adjusted odds ratio, 3.0; P = .03) and RV-C (adjusted odds ratio, 3.7; P < .001) etiology were associated with the current use of asthma medication. The highest risk was found among patients with RV-C, atopic dermatitis, and fever (adjusted odds ratio, 5.0; P = .03). CONCLUSIONS: Severe bronchiolitis caused by RV-A and RV-C was associated with earlier initiation and prolonged use of asthma control medication. The risk was especially high when bronchiolitis was associated with RV-C, atopic dermatitis, and fever. American Academy of Allergy, Asthma & Immunology 2020-02 2019-09-11 /pmc/articles/PMC7012669/ /pubmed/31520837 http://dx.doi.org/10.1016/j.jaip.2019.08.043 Text en © 2019 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Bergroth, Eija Aakula, Matilda Elenius, Varpu Remes, Sami Piippo-Savolainen, Eija Korppi, Matti Piedra, Pedro A. Bochkov, Yury A. Gern, James E. Camargo, Carlos A. Jartti, Tuomas Rhinovirus Type in Severe Bronchiolitis and the Development of Asthma |
title | Rhinovirus Type in Severe Bronchiolitis and the Development of Asthma |
title_full | Rhinovirus Type in Severe Bronchiolitis and the Development of Asthma |
title_fullStr | Rhinovirus Type in Severe Bronchiolitis and the Development of Asthma |
title_full_unstemmed | Rhinovirus Type in Severe Bronchiolitis and the Development of Asthma |
title_short | Rhinovirus Type in Severe Bronchiolitis and the Development of Asthma |
title_sort | rhinovirus type in severe bronchiolitis and the development of asthma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012669/ https://www.ncbi.nlm.nih.gov/pubmed/31520837 http://dx.doi.org/10.1016/j.jaip.2019.08.043 |
work_keys_str_mv | AT bergrotheija rhinovirustypeinseverebronchiolitisandthedevelopmentofasthma AT aakulamatilda rhinovirustypeinseverebronchiolitisandthedevelopmentofasthma AT eleniusvarpu rhinovirustypeinseverebronchiolitisandthedevelopmentofasthma AT remessami rhinovirustypeinseverebronchiolitisandthedevelopmentofasthma AT piipposavolaineneija rhinovirustypeinseverebronchiolitisandthedevelopmentofasthma AT korppimatti rhinovirustypeinseverebronchiolitisandthedevelopmentofasthma AT piedrapedroa rhinovirustypeinseverebronchiolitisandthedevelopmentofasthma AT bochkovyurya rhinovirustypeinseverebronchiolitisandthedevelopmentofasthma AT gernjamese rhinovirustypeinseverebronchiolitisandthedevelopmentofasthma AT camargocarlosa rhinovirustypeinseverebronchiolitisandthedevelopmentofasthma AT jarttituomas rhinovirustypeinseverebronchiolitisandthedevelopmentofasthma |